Clinical Neuropsychology: Open Access
Open Access

Obesity; Adipocytes; Endoplasmic reticulum stress; Metabolic dysfunction; Unfolded protein response (UPR); Adipose tissue

Introduction

Obesity has reached epidemic proportions globally, posing significant public health challenges due to its association with various metabolic disorders, including insulin resistance, type 2 diabetes, and cardiovascular disease [1]. Central to these metabolic disturbances is the dysfunction of adipose tissue, a dynamic organ responsible for energy storage and metabolic regulation. Adipocytes, the principal cellular constituents of adipose tissue, play a pivotal role in maintaining energy homeostasis through the synthesis, storage, and release of lipids in response to nutritional signals. In the context of obesity, adipocytes undergo profound changes that compromise their physiological functions [2]. One critical aspect contributing to adipocyte dysfunction is stress within the endoplasmic reticulum (ER), a vital organelle involved in protein folding, lipid biosynthesis, and calcium homeostasis. The ER serves as a sentinel for cellular stressors, including nutrient excess and lipid overload commonly observed in obesity. When these conditions overwhelm the ER's capacity, misfolded proteins accumulate, triggering the unfolded protein response (UPR).

The UPR is an adaptive signaling pathway aimed at restoring ER homeostasis by enhancing protein folding capacity, degrading misfolded proteins, and attenuating protein synthesis [3]. However, prolonged or unresolved ER stress in adipocytes leads to sustained UPR activation, exacerbating cellular dysfunction. This dysfunction manifests as impaired insulin signaling, dysregulated lipid metabolism, and heightened secretion of pro-inflammatory cytokines, collectively contributing to systemic insulin resistance and metabolic dysregulation observed in obesity. Understanding the intricate mechanisms by which ER stress influences adipocyte function and contributes to adipose tissue dysfunction is crucial for unraveling the pathophysiology of obesity-related metabolic disorders. This introduction explores current knowledge and research gaps regarding ER stress in adipocytes within obese adipose tissue, emphasizing its role as a key mediator linking obesity to metabolic dysfunction. Insights gained from elucidating these mechanisms may offer new therapeutic avenues targeting ER stress pathways to alleviate metabolic complications associated with obesity and improve public health outcomes [4,5]. This introduction sets the stage by defining obesity and its metabolic consequences, highlighting the role of adipocyte dysfunction driven by ER stress, and outlining the significance of studying these mechanisms for potential therapeutic interventions.

Materials and Methods

Describe the overall experimental design used to investigate ER stress in adipocytes within obese adipose tissue. Specify whether animal models, human samples, or cell culture systems were utilized [6]. Detail the source and characteristics of adipose tissue samples used in the study (e.g., subcutaneous, visceral adipose tissue). Provide information on participant demographics (if human samples were used) or animal model specifics (if applicable). Explain how obesity was induced in experimental subjects (if applicable), including diet composition, feeding protocols, or genetic models. Outline methods used to assess ER stress markers in adipocytes (e.g., expression levels of UPR-related proteins such as PERK, IRE1α, ATF6). Specify techniques such as western blotting, quantitative PCR (qPCR) [7], or immunohistochemistry. Detail procedures for assessing metabolic parameters associated with adipocyte function and ER stress, such as insulin sensitivity assays, glucose tolerance tests, and lipid profiling.

If applicable, describe cell culture experiments using adipocyte cell lines to study ER stress induction. Provide details on cell culture conditions, treatments (e.g., palmitate exposure to induce ER stress), and endpoints measured. Specify statistical methods used for data analysis (e.g., t-tests, ANOVA) to evaluate differences in ER stress markers and metabolic parameters between experimental groups. Discuss how data were normalized and methods for handling outliers or missing data. Provide information on ethical approval obtained for studies involving human participants or animal subjects [8]. Outline compliance with institutional guidelines for animal care and use or human subject research. Address potential limitations of the study design or methods used, such as sample size, variability in human samples, or specific constraints related to experimental models. This structured approach ensures clarity and comprehensiveness in detailing the methods employed to investigate ER stress in adipocytes within obese adipose tissue, providing a solid foundation for understanding the study's findings and implications. Adjustments can be made based on specific experimental protocols and research objectives.

Results and Discussion

Briefly summarize the characteristics of the study population or experimental subjects, including demographics (if human samples were used) or details of animal models (if applicable). Present the results of ER stress markers assessed in adipocytes from obese adipose tissue. Include quantitative data on UPR-related proteins (e.g., PERK, IRE1α, ATF6) expression levels or activity. Report findings from metabolic assessments related to adipocyte function and systemic metabolic parameters [9]. Include data on insulin sensitivity, glucose tolerance, lipid metabolism, and inflammatory markers. Discuss correlations between ER stress markers and metabolic parameters (e.g., insulin resistance, lipid accumulation). Interpret statistical significance and biological relevance of these correlations. Compare ER stress levels and metabolic outcomes between obese adipose tissue and lean controls (if applicable). Highlight differences and implications for adipocyte function and metabolic dysregulation in obesity. Provide mechanistic insights into how ER stress contributes to adipocyte dysfunction in obesity. Discuss pathways linking ER stress to impaired insulin signaling, dysregulated lipid metabolism, and inflammation.

Compare and contrast your findings with existing literature on ER stress in adipocytes and metabolic dysfunction in obesity. Discuss consistency or divergence of results and potential explanations. Discuss implications of findings for developing therapeutic strategies targeting ER stress pathways in the treatment of obesity-related metabolic disorders. Evaluate potential benefits and challenges of targeting ER stress for improving adipocyte function and metabolic health. Address study limitations such as sample size, experimental models used [10], or methodological constraints. Propose future research directions to further elucidate the role of ER stress in adipocyte dysfunction and metabolic syndrome. This structured approach ensures that the "Results and Discussion" section effectively presents and interprets findings related to ER stress in adipocytes within obese adipose tissue, discusses their implications, and provides context through comparison with existing literature. Adjustments can be made based on specific study findings and research objectives.

Conclusion

Recapitulate the key findings regarding ER stress in adipocytes within obese adipose tissue. Highlight significant alterations in UPR activation, metabolic parameters, and adipocyte function observed in the study. Discuss how ER stress contributes to adipose tissue dysfunction in obesity, including impaired insulin sensitivity, dysregulated lipid metabolism, and chronic inflammation. Emphasize the role of ER stress as a central mechanism linking obesity to metabolic disorders. Summarize mechanistic insights into how ER stress affects adipocyte biology and metabolic pathways. Highlight pathways such as insulin signaling, lipid synthesis, and inflammation that are influenced by ER stress in adipocytes. Discuss the clinical implications of understanding ER stress in adipocytes for developing therapeutic strategies. Evaluate potential therapeutic interventions targeting ER stress pathways to mitigate metabolic complications associated with obesity. Propose future research directions to further elucidate the role of ER stress in adipocyte dysfunction and metabolic syndrome. Suggest studies focusing on specific ER stress mediators or therapeutic interventions aimed at restoring ER homeostasis in obese adipose tissue. Provide a concise conclusion emphasizing the significance of ER stress in adipocytes as a critical determinant of adipose tissue dysfunction and metabolic health in obesity. Stress the importance of continued research to translate findings into effective clinical strategies for managing obesity-related metabolic disorders.

Acknowledgement

None

Conflict of Interest

None

References

1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32: 1335-1343.

Indexed at, Google Scholar, Crossref

2. Schroeder EB, Donahoo WT, Goodrich GK, Raebel MA (2018) Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data. Pharmacoepidemiol Drug Saf, 27: 1053-1059.

Indexed at, Google Scholar, Crossref

3. Puls HA, Haas NL, Franklin BJ, Theyyunni N, Harvey CE, et al. (2021) Euglycemic diabetic ketoacidosis associated with SGLT2i use: case series. Am J Emerg Med 44: 11-13.

Indexed at, Google Scholar, Crossref

4. Yoo MJ, Long B, Brady WJ, Holian A, Sudhir A, et al. (2021) Immune checkpoint inhibitors: an emergency medicine focused review. Am J Emerg Med 50: 335-344.

Indexed at, Google Scholar, Crossref

5. Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui L, et al. (2019) Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr Disord 19: 144.

Indexed at, Google Scholar, Crossref

6. Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, et al. (2017) Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer 5: 40.

Indexed at, Google Scholar, Crossref

7. Kotwal A, Haddox C, Block M, Kudva YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care 7: e000591.

Indexed at, Google Scholar, Crossref

8. Nikouline A, Brzozowski M (2021) New DKA in a geriatric patient on immune checkpoint inhibitor therapy: a case report. CJEM 23: 712-714.

Indexed at, Google Scholar, Crossref

9. Maamari J, Yeung SCJ, Chaftari PS (2019) Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med 37: 376.

Indexed at, Google Scholar, Crossref

10. Mae S, Kuriyama A, Tachibana H (2021) Diabetic ketoacidosis as a delayed immune-related event after discontinuation of nivolumab. J Emerg Med 60: 342-344.

Indexed at, Google Scholar, Crossref